Determination Method for the 50% Hemolysis Rate (CH50): Principle, Procedure, and Applications

The 50% hemolysis rate assay, commonly known as the CH50 test, is a sensitive quantitative method used to measure complement-mediated hemolytic activity in serum and to characterize complement-dependent cytolytic reactions. This article provides a comprehensive overview of the assay principle, sample requirements, step-by-step testing procedure, calculation formulas, quality control measures, and typical applications in clinical immunology, vaccine quality control, and medical device hemocompatibility evaluation.

Technical Overview

The 50% hemolysis rate, most frequently expressed as CH50 (50% complement hemolytic activity), defines the amount or dilution of serum complement required to lyse 50% of a standardized suspension of antibody-sensitized erythrocytes under strictly controlled reaction conditions. The assay is based on the classical complement pathway: when sheep erythrocytes coated with specific anti-erythrocyte antibody (hemolysin or amboceptor) are incubated with fresh serum, the full complement cascade C1 through C9 is activated, forming the membrane attack complex on the erythrocyte surface and releasing hemoglobin into the supernatant.

The relationship between the amount of complement and the degree of hemolysis follows a sigmoidal dose-response curve rather than a linear one. Because the curve is steepest at its midpoint, small changes in complement activity produce the largest measurable change in hemolysis near the 50% endpoint. This is why the 50% hemolysis point, rather than complete hemolysis, is selected as the quantitative endpoint: it provides maximum analytical sensitivity and reproducibility.

The sigmoidal relationship is linearized using the von Krogh equation, which converts the hemolysis curve into a straight line from which the exact serum volume corresponding to 50% hemolysis can be interpolated. One CH50 unit is defined as the quantity of complement that lyses 50% of the indicator cells in the standardized system, and results are reported as CH50 units per milliliter of serum.

Testing Samples

Human Serum

Venous blood is collected into plain tubes without anticoagulant, allowed to clot at room temperature for no more than 60 minutes, and centrifuged to separate serum. Because complement proteins are labile, serum should be tested within a few hours or stored at minus 70 degrees Celsius or below to preserve activity. Repeated freeze-thaw cycles and prolonged room-temperature storage must be avoided, as they cause significant loss of complement activity and falsely low results.

Animal Serum

Serum from laboratory animals such as rabbits, guinea pigs, rats, and mice is used in preclinical studies, complement activity monitoring, and as a complement source in immunoassays. Guinea pig serum is historically the reference complement source in complement fixation tests due to its high classical pathway activity.

Biological Products and Material Extracts

Vaccine bulks, immune globulin preparations, and extracts of medical device materials prepared according to ISO 10993 series and GB/T 16886 series standards may be evaluated for their effect on complement activity or for intrinsic hemolytic properties. Extracts are typically prepared with saline or other polar solvents under conditions that simulate clinical exposure.

Testing Items

The 50% hemolysis rate determination typically covers the following analytical items:

• Total classical pathway complement activity (CH50), reported in units per milliliter.
• Alternative pathway complement activity (ACH50), measured with rabbit erythrocytes and a magnesium-EGTA buffer that blocks the classical pathway.
• Lectin pathway activity, assessed with specific activators of the MBL pathway where required.
• Percent hemolysis of individual dilutions, used to construct the dose-response curve.
• Hemolysis rate of medical device material extracts, evaluated against the 5% hemolysis threshold in accordance with ISO 10993-4, ASTM F756, and GB/T 16886.4.
• Complement consumption or inhibition caused by immune complexes, drugs, or biomaterials.

Testing Methods

Reagents and Equipment

• Sheep erythrocytes (for the classical pathway) or rabbit erythrocytes (for the alternative pathway), washed and standardized to the required cell concentration.
• Rabbit anti-sheep erythrocyte hemolysin (amboceptor), titrated to determine the optimal sensitizing dilution.
• Veronal-buffered saline containing calcium and magnesium ions, which preserves complement activity during the reaction.
• Fresh or properly frozen reference serum with a known CH50 value, used as a positive control.
• A spectrophotometer or microplate reader set to the hemoglobin absorption wavelength of 540 to 545 nanometers.
• Water bath or incubator calibrated to 37 degrees Celsius, centrifuge, and calibrated pipettes.

Test Procedure

The classical spectrophotometric tube method proceeds through the following steps:

• Wash sheep erythrocytes three times in buffered saline and prepare a standardized cell suspension of defined concentration.
• Sensitize the erythrocytes with the optimal dilution of hemolysin at 37 degrees Celsius, then wash to remove unbound antibody.
• Prepare serial dilutions of the test serum in veronal-buffered saline containing calcium and magnesium.
• Mix each serum dilution with a fixed volume of sensitized erythrocytes and incubate at 37 degrees Celsius for 30 to 60 minutes with gentle mixing.
• Set up parallel controls: a 100% hemolysis control using water or ammonium chloride solution, a reagent blank with cells and buffer only, and a positive control serum of known activity.
• Centrifuge the reaction mixtures to pellet intact cells and transfer the supernatants to measurement vessels.
• Measure the absorbance of each supernatant at 541 nanometers against the blank.

Calculation of Results

The percentage of hemolysis for each tube is calculated as the ratio of the sample absorbance, after subtraction of the blank, to the absorbance of the 100% hemolysis control, multiplied by 100. The results are then linearized using the von Krogh transformation: the logarithm of the ratio x divided by (1 minus x), where x is the fractional hemolysis, is plotted against the logarithm of the serum volume or dilution. The resulting straight line intercepts the zero point of the y-axis at exactly 50% hemolysis, and the corresponding serum volume is read directly as the CH50 value. The final result is expressed as CH50 units per milliliter, corrected for the dilution factor of the original sample.

For medical device hemocompatibility testing, the hemolysis rate is calculated as the sample absorbance minus the negative control absorbance, divided by the positive control absorbance minus the negative control absorbance, multiplied by 100%. A hemolysis rate below 5% is generally considered acceptable, and testing is conducted in accordance with ISO 10993-4, ASTM F756, and GB/T 16886.4 by accredited third-party laboratories.

Quality Control and Interference Factors

• Serum must be separated promptly and stored frozen, since complement degrades rapidly at room temperature.
• Erythrocyte concentration and antibody sensitization level must be standardized, as deviations shift the hemolysis curve.
• Chelating agents such as EDTA and citrate inhibit complement activation and render serum unsuitable for the assay unless specifically evaluated for their inhibitory effect.
• Hemolyzed, lipemic, or contaminated samples interfere with the spectrophotometric reading and should be rejected.
• Incubation time and temperature must be strictly controlled because the reaction is temperature dependent.
• Each run must include reference serum controls, and results are valid only when control values fall within established limits.

Applications

Clinical Immunology and Diagnostics

CH50 measurement is a first-line screening test for complement system abnormalities. Markedly reduced or absent CH50 activity suggests hereditary deficiencies of classical pathway components, while moderately reduced values are observed in immune complex diseases such as systemic lupus erythematosus, post-streptococcal glomerulonephritis, cryoglobulinemia, and certain infections. Serial monitoring of CH50 helps assess disease activity and complement consumption during therapy.

Vaccine and Biologics Quality Control

Complement-dependent hemolysis assays are used in potency testing of certain vaccines and in evaluating complement-fixing antibodies. The 50% hemolysis inhibition endpoint is applied in pharmacopoeial methods for leptospirosis vaccine potency evaluation, where the antibody level that inhibits 50% of the hemolytic reaction is determined relative to a reference preparation.

Medical Device Hemocompatibility Evaluation

Blood-contacting devices and biomaterials are evaluated for hemolytic properties as part of the biological evaluation required by ISO 10993-4 and GB/T 16886.4. Direct contact tests and indirect extract tests quantify hemoglobin release from human or rabbit blood, and materials are classified as hemolytic or non-hemolytic based on the measured hemolysis rate relative to the 5% threshold specified in ASTM F756.

Research and Drug Development

The assay is widely used in immunology research to quantify complement activation or inhibition by monoclonal antibodies, small molecules, nanoparticles, and novel biomaterials, supporting immunotoxicity assessment during preclinical development.

FAQ

What is the difference between CH50 and ACH50?

CH50 measures the total activity of the classical complement pathway using antibody-sensitized sheep erythrocytes in buffer containing calcium and magnesium, whereas ACH50 measures the alternative pathway using rabbit erythrocytes in buffer containing magnesium and EGTA, which chelates calcium and blocks classical pathway activation. Measuring both allows localization of a complement defect to a specific pathway.

Why is the 50% endpoint used instead of 100% hemolysis?

The complement-hemolysis dose-response curve is sigmoidal and flattens near complete hemolysis, where large changes in complement concentration produce only small changes in hemolysis. At the 50% point the curve is steepest, so the assay is most sensitive to small differences in complement activity at this endpoint.

What is the typical reference range for CH50 in human serum?

Reference intervals vary between laboratories and methods, but healthy adult serum generally falls in the range of approximately 50 to 100 CH50 units per milliliter, or equivalently 30 to 60 units per milliliter in some assay systems. Each laboratory must establish and validate its own reference range for the specific method and population it serves.

How should samples be handled to preserve complement activity?

Serum should be separated from clotted blood within two hours of collection and tested the same day. If testing is delayed, samples must be aliquoted and stored at minus 70 degrees Celsius or below, avoiding repeated freeze-thaw cycles. Plasma collected with EDTA or citrate is unsuitable because chelation inactivates complement.

What hemolysis rate is acceptable for medical devices?

Under ISO 10993-4, ASTM F756, and GB/T 16886.4, a material or device is generally considered non-hemolytic when the measured hemolysis rate is below 5%, while values of 5% or above indicate hemolytic potential and require further evaluation or material modification.

Can the assay be performed in a microplate format?

Yes, miniaturized microplate versions of the CH50 assay are widely used in research and high-throughput screening. They retain the same principle of endpoint interpolation at 50% hemolysis but require careful validation of volume ratios, incubation conditions, and absorbance wavelength to ensure equivalence with the reference tube method.